You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

235 Results
*/
Document
New
Jan 2025
*/
Document
New
Jan 2025
Document
New
Jan 2025
Document
New
Jan 2025
The Radiation Treatment Program ensures timely access to safe, evidence-based, high-quality radiation treatment. To improve patient experience and...
Les informations suivantes répondent à de nombreuses questions fréquemment posées par les médecins de première ligne au sujet du rapport d'activité...
Drug
Other Name(s): Jakavi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
Exceptional Access Program
    ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ruxolitinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025

Pages